BioInvent: BI-1206 & pembro combo enters phase 2a, targeting 1L NSCLC & 1L UM
BioInvent has completed the phase 1 portion of its trial evaluating BI-1206 in combination with pembrolizumab across solid tumors and will initiate the phase 2a expansion, targeting 1L NSCLC and 1L uveal melanoma (UM), with enrollment expected in H2 2025. Initial data readouts are anticipated in 20
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.